High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
暂无分享，去创建一个
C. Klein | S. Endres | S. Kobold | J. Ogonek | P. Duewell | C. Heise | F. Rataj | Erwin van Puijenbroek | Severin J. Jacobi | S. Stoiber | F. Asang | Nicholas Tokarew | B. Cadilha | Nicholas J A Tokarew | Nicholas J. A. Tokarew